You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 18, 2024

~ Buy the DUEXIS (famotidine; ibuprofen) Drug Profile, 2024 PDF Report in the Report Store ~

DUEXIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Duexis, and when can generic versions of Duexis launch?

Duexis is a drug marketed by Horizon and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in fifteen countries.

The generic ingredient in DUEXIS is famotidine; ibuprofen. There are eighteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the famotidine; ibuprofen profile page.

DrugPatentWatch® Generic Entry Outlook for Duexis

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for DUEXIS
Drug Prices for DUEXIS

See drug prices for DUEXIS

Drug Sales Revenue Trends for DUEXIS

See drug sales revenues for DUEXIS

Paragraph IV (Patent) Challenges for DUEXIS
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
DUEXIS Tablets famotidine; ibuprofen 800 mg/26.6 mg 022519 1 2011-12-06

US Patents and Regulatory Information for DUEXIS

DUEXIS is protected by five US patents.

Patents protecting DUEXIS

Methods and medicaments for administration of ibuprofen
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

Stable compositions of famotidine and ibuprofen
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Stable compositions of famotidine and ibuprofen
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Stable compositions of famotidine and ibuprofen
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Stable compositions of famotidine and ibuprofen
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Horizon DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for DUEXIS

When does loss-of-exclusivity occur for DUEXIS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06269894
Estimated Expiration: ⤷  Try a Trial

Patent: 07275360
Estimated Expiration: ⤷  Try a Trial

Austria

Patent: 39747
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0714937
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 15496
Estimated Expiration: ⤷  Try a Trial

Patent: 57928
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1257800
Estimated Expiration: ⤷  Try a Trial

Patent: 1516368
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 43637
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 19288
Estimated Expiration: ⤷  Try a Trial

Patent: 43637
Estimated Expiration: ⤷  Try a Trial

Patent: 38919
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 8732
Estimated Expiration: ⤷  Try a Trial

Patent: 6425
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 09501801
Estimated Expiration: ⤷  Try a Trial

Patent: 09543885
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 5846
Estimated Expiration: ⤷  Try a Trial

Patent: 4200
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 43637
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 43637
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0900423
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 80747
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DUEXIS around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 2043637 PROCÉDÉS ET MÉDICAMENTS DESTINÉS À L'ADMINISTRATION D'IBUPROFÈNE (METHODS AND MEDICAMENTS FOR ADMINISTRATION OF IBUPROFEN) ⤷  Try a Trial
Spain 2380747 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2007012022 ⤷  Try a Trial
European Patent Office 1919288 MEDICAMENTS CONTENANT FAMOTIDINE ET IBUPROFENE, ET ADMINISTRATION DESDITS MEDICAMENTS (MEDICAMENTS CONTAINING FAMOTIDINE AND IBUPROFEN AND ADMINISTRATION OF SAME) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.